Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has made a 246.53% comeback from a 12-month low price of $1.01. It was seen 4.17% higher, changing the price to $3.5, when the closing bell rang on 11/24/2017. At recent session, the prices were hovering between $3.3337 and $3.52. This company shares are 55.43% off its target price of $5.44 and the current market capitalization stands at $296.24M. The recent change has given its price a 28.02% lead over SMA 50 and 3.24% lead over its 52-week high. The stock witnessed 21.95% gains, 25.9% gains and 63.55% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found CPRX’s volatility during a week at 5.87% and during a month it has been found around 6.07%.Catalyst Pharmaceuticals, Inc. (CPRX) Top Holders
Institutional investors currently hold around $120 million or 42.3% in CPRX stock. Look at its top three institutional owners. Broadfin Capital, Llc owns $23.16 million in Catalyst Pharmaceuticals, Inc., which represents roughly 7.82% of the company’s market cap and approximately 19.3% of the institutional ownership. Similar statistics are true for the second largest owner, Baker Bros. Advisors Lp, which owns 5,102,153 shares of the stock are valued at $17.14 million. The third largest holder is Venbio Select Advisor Llc, which currently holds $15.58 million worth of this stock and that ownership represents nearly 5.26% of its market capitalization.Catalyst Pharmaceuticals, Inc. 13F Filings
At the end of 09/30/2017 reporting period, 35 institutional holders increased their position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by some 3,233,527 shares, 21 decreased positions by 1,574,151 and 29 held positions by 30,845,026. That puts total institutional holdings at 35,652,704 shares, according to SEC filings. The stock grabbed 14 new institutional investments totaling 1,604,910 shares while 3 institutional investors sold out their entire positions totaling 98,802 shares.Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Insider Trades
Multiple company employees have indulged in significant insider trading. Catalyst Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that President and CEO Mcenany Patrick J has acquired 20,000 shares of Catalyst Pharmaceuticals, Inc. (CPRX) in trading session dated Sep. 05, 2017. These shares are worth $51,600 and were traded at $2.58 each. The SEC filing shows that O’Keeffe Charles B performed a purchase of 20,000 shares. The Director added these shares by way of transaction on Jul. 12, 2016. The company’s shares were assimilated at $0.81 per share worth to an investment of some $16,200 on account of O’Keeffe Charles B.
Director, Coelho Philip H, purchased 15,000 common shares of Catalyst Pharmaceuticals, Inc. (CPRX) in the open market. In a transaction dated Jun. 17, 2016, the shares were bought at an average price of $0.76, giving away a sum of $11,400. After this purchase, 173,287 common shares of CPRX are directly owned by the insider, with total stake valued at $606,505.
In the transaction dated Jun. 14, 2016, the great number of shares acquired came courtesy the Director; Denkhaus Donald A added a total of 50,000 shares at an average price of $0.65, amounting to approximately $32,500. The insider now directly owns 100,000 shares worth $350,000.Catalyst Pharmaceuticals, Inc. (CPRX) Analyst Guide
Several analysts have released their opinion on Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX), with 4 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1 average brokerage recommendation.